# Autonomix Medical, Inc.

**AMIX**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001617867

# None

**No letter**

3 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $7.6M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data, degenerate in...<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through Jun 15, 2026<br>138 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $1.85<br>2026-10-30; market equity $1.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received May 27, 2026*

We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency ("RF") ablation, enabling a "sense, treat, verify" approach intended to improve the precision and consistency of nerve-targeted therapies. The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 8.1** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (50.9%) | (6.6%) | 8.1 | 803 | 2026-03-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 62.3** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *four consecutive discrete net-income quarters are required; found 4* | | | | | |
| Altman Z double-prime | (35.14) | (0.35) | 84.2 | 748 | 2026-03-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 4.45x | 2.92x | 40.5 | 829 | 2026-03-31 |
| **Growth and financing** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 3* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | not computable | 2.2% | | | |
| *four annual observations are required; found 3* | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | |
| *prior share count is 20 days earlier* | | | | | |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 3.1 months |
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (78.7%) | 7.3% | 4 |
| Distance from 52-week high | (92.5%) | (28.7%) | 4 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | (699.4%) | (1.0%) | 2 |
| Book value to price | 1.80 | 0.28 | 94 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (1.76) | (0.14) | 4 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-03-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $3.5M |
| Operating cash flow, four quarters | -$13.2M |
| Months of runway | 3.1 |
| Days since last periodic filing | 79 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $377,597 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$16.7M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.3M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 3 | assets | us-gaap:Assets | $7.6M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 4 | assets | us-gaap:Assets | $9.8M | 2025-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 5 | current assets | us-gaap:AssetsCurrent | $7.6M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $1.7M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$67.1M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$17.0M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 9 | book equity | us-gaap:StockholdersEquity | $5.9M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 10 | liabilities | us-gaap:Liabilities | $1.7M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 11 | revenue | us-gaap:Revenues | $0 | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 12 | revenue | us-gaap:Revenues | $0 | 2025-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 13 | revenue | us-gaap:Revenues | $0 | 2024-03-31 | 2025-05-29 | 10-K | 25-018831 |
| 14 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10,000 | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 15 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $12,000 | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 16 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$16.7M | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 17 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2026-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 18 | current assets | us-gaap:AssetsCurrent | $9.6M | 2025-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $1.7M | 2025-03-31 | 2026-05-27 | 10-K | 26-018573 |
| 20 | assets | us-gaap:Assets | $9.4M | 2024-03-31 | 2025-05-29 | 10-K | 25-018831 |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 11,409,344 | 2026-06-10 | 2026-06-15 | 10-K/A | 26-020686 |
| 22 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 11,409,344 | 2026-05-21 | 2026-05-27 | 10-K | 26-018573 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.